Cardiol Advances Phase II/III Clinical Trials
For those of you who may be new to the story, let’s begin with a ...
Read MoreCore One Labs ($COOL) Brings the Heat
Ironically known by the ticker “COOL” in Canada – Core One is anything but, as they remain on fire ...
Read MoreShould I Put A Bit of Coin into Bitcoin?
There are valid reasons for many consider to traditional banking a heavily outdated system… but is Crypto the ...
Read MoreCoping with Life Post-Honeymoon
Much like a new relationship, the initial passion period is unforgettable. As it continues to develop, stabilize, and mature, you’re ...
Read MoreWe Know the Drill. Do You?
As we know, the world of electric vehicles is on center stage right now. Car-maker giants ...
Read MoreFrom Coffee to Clinical Trials
No market catalysts in the world of fungi have been touted more than the forward-looking ones regarding the ...
Read MoreAre Your Blue Chips in the Red?
Here at Edge, we mainly focus on small cap stocks and emerging companies in the venture ...
Read MoreWhat Makes Hulk So Incredible?
As sustainable, animal–friendly, and environmentally conscious food companies surge in popularity this last year, it takes a little ...
Read MoreHow to Start Investing: Choosing a Broker
There are dozens of brokerages online that suddenly make investing easy, at the touch of your phone ...
Read MoreIs this Technology Company Massively Undervalued?
Digital health. Gaming. Blockchain. AR/VR. Cybersecurity. Cloud computing. No, we’re not just naming all the trendiest sectors ...
Read MoreEdge-ucation / Market Commentary
Options Trading for Dummies Pt. 2
Last week, we went through the basics of options with you. What types of options there ...
Read MoreFrom Caterpillar To Butterfly
There are many things that are very good about the Very Good Food Company. Their ...
Read MoreJazz Pharmaceuticals Set to Acquire GW Pharmaceuticals In $7.2 Billion Transaction
We first came across GW Pharma in mid-2020, at a time when they were a ...
Read MoreOur case studies
Featured case studies
Subscribe Today
Get 30+ hours of analyst research directly in your inbox weekly. Sign-up today to stay on top of the market.
